GlaxoSmithKline scores a PhIII success for marathon shingles vaccine study

December 18, 2014 12:46 PM

18 0

GlaxoSmithKline ($GSK) got some good news for its big vaccines group, scoring a pivotal Phase III win for its shingles vaccine HZ/su more than four years after the study was launched.

The herpes zoster jab reduced the risk of shingles by 97.2% in a crowd of patients in the 50-plus age group. And the outcome marks the end of a trial that was launched way back in 2010 as investigators recruited 16,000 people in 18 countries. The full Phase III program includes 37,000 people.

Read more

To category page